AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and compliance officer. You may begin. Thank you. Hello, everyone. Thank you for joining us for Obscilla's 2025 second quarter earnings call. I'm Trent Steinmart, Obscilla's chief legal and compliance officer. Dr. Carl Hanson, Obscilla's president and CEO, and Andrew Booth, Obscilla's chief financial officer are also on the call. During today's call, we anticipate making projections and forward-looking statements based on our current expectations and following the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results may differ materially due to several factors outlined in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities Exchange Commission. Obscilla is not obligated to update any forward-looking statements, whether due to new information, future events, or otherwise. Our presentation today, including our earnings press release and SEC filings issued earlier today, are available on our Investor Relations website. The information we provide about our antibody therapy pipeline is for the benefit of the investment community is not intended to be promotional. As we transition to our prepared remarks, please note that all dollars referenced are U.S. dollars. After our prepared remarks, we will open the lines for questions and answers. Now I'll turn the call over to Carl. Thanks, Trinh, and thank you everyone for joining us today. This quarter we achieved a major company milestone, receiving Health Canada authorization to initiate Obscilla's first two clinical trials for ABCL 635 and ABCL 575. Today I'm pleased to announce that dosing has begun in our Phase 1 clinical trial evaluating ABCL 635 for moderate to severe vasomotor symptoms. This marks completion of the transition from a platform compan...